{"analyses":[{"ciLowerLimit":"0.306","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.128","estimateComment":"The hazard ratio was estimated using a stratified Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1061","paramType":"Hazard Ratio (HR)","paramValue":"0.587","statisticalMethod":"stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"97.1","upperLimit":"99.8","value":"99.3"},{"groupId":"OG001","lowerLimit":"93.1","upperLimit":"98.0","value":"96.2"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.8","upperLimit":"98.2","value":"96.4"},{"groupId":"OG001","lowerLimit":"90.0","upperLimit":"96.1","value":"93.7"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.1","upperLimit":"96.5","value":"93.8"},{"groupId":"OG001","lowerLimit":"84.8","upperLimit":"93.6","value":"90.1"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.0","upperLimit":"95.8","value":"92.5"},{"groupId":"OG001","lowerLimit":"76.2","upperLimit":"91.4","value":"85.5"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"275"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization until death from any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL: Placebo + Rituximab + Lenalidomide"},{"description":"Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG002","title":"MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG003","title":"MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"NUMBER","populationDescription":"FL Full Analysis Set. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"FL Population: Kaplan-Meier Estimates of Overall Survival","type":"SECONDARY","unitOfMeasure":"percent probability"}